Nanobiotix S.A. Announces Closing of Global Offering of ADSs, Ordinary Shares, and Pre-Funded Warrants

On May 21, 2026, Nanobiotix S.A. entered into an underwriting agreement for a global offering consisting of 225,373 American Depositary Shares (ADSs) in the United States at $38.98 per ADS, and 1,959,289 ordinary shares in Europe at €33.60 per share. The offering also includes 345,099 pre-funded warrants to purchase an equivalent number of ordinary shares at an exercise price of €0.03 per share, exercisable for ten years. Additionally, underwriters exercised an over-allotment option for 33,805 ADSs. The global offering is expected to close around May 26, 2026. The securities were issued without preferential rights for existing shareholders. The pre-funded warrants include a beneficial ownership limitation of 9.99%, adjustable up to 19.99% or 24.99% depending on French foreign investment regulations. Proceeds are intended for general corporate purposes as outlined in the shelf registration on Form F-3. The filing also details customary representations, warranties, and the governance of the warrants under French law.